Literature DB >> 3871117

T cells with FC receptors in myeloma; suppression of growth and secretion of MOPC-315 by T alpha cells.

S Müller, R G Hoover.   

Abstract

We have previously demonstrated that 1) BALB/c mice and patients with IgA myeloma developed a marked expansion of T cells with surface IgA-Fc receptors (T alpha cells), 2) the FcR alpha were induced by direct interaction of soluble myeloma IgA with T cells, and 3) the T alpha cells induced in IgA myeloma were Lyt-1-2+, IgA isotype-specific suppressor cells in normal immune responses. These findings established that the host with IgA myeloma responds to the large amounts of Ig produced by the tumor by activating an otherwise normal IgA isotype-specific suppressor circuit. In the present studies, we extend our previous observations and show that T alpha cells can suppress both the growth and secretion of MOPC-315 myeloma tumor cells. Thus, the isotype-specific immunoregulatory circuit activated in myeloma is capable of suppressing tumor cells as well as normal cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871117

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  In vitro inhibition of tumor B cell growth by IgG-BF-producing Fc gamma RII+ T cell hybridoma and by immunoglobulin G-binding factors.

Authors:  C Mathiot; S Amigorena; J Moncuit; C Sautès; W H Fridman; J L Teillaud
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 2.  Regulation of IgA synthesis and immune response by T cells and interleukins.

Authors:  J R McGhee; J Mestecky; C O Elson; H Kiyono
Journal:  J Clin Immunol       Date:  1989-05       Impact factor: 8.317

3.  A human T-cell receptor recognizes 'O'-linked sugars from the hinge region of human IgA1 and IgD.

Authors:  P M Rudd; F Fortune; T Patel; R B Parekh; R A Dwek; T Lehner
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

4.  Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.

Authors:  C Mathiot; J L Teillaud; M Elmalek; V Mosseri; L Euller-Ziegler; A Daragon; B Grosbois; J L Michaux; T Facon; J F Bernard
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

5.  Binding of human IgA1 to rat peritoneal macrophages.

Authors:  A Gorter; P S Hiemstra; E A van der Voort; L A van Es; M R Daha
Journal:  Immunology       Date:  1988-06       Impact factor: 7.397

6.  Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.

Authors:  R G Hoover; C Lary; R Page; P Travis; R Owens; J Flick; J Kornbluth; B Barlogie
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.